

Attorney Docket No.: DEX-0471
Inventors: Sun et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-9 (canceled)

Claim 10 (original): A method of identifying potential therapeutic agents for use in imaging and treating breast cancer comprising screening molecules for an ability to bind to BSG or alter expression of BSG relative to BSG in the absence of the agent wherein the ability of a molecule to bind to BSG or alter expression of BSG is indicative of the molecule being useful in imaging and treating breast cancer.

Claim 11 (original): An antibody which specifically binds a BSG wherein said BSG comprises Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4 or SEQ ID NO:10) or Mam005 (SEQ ID NO:3).

Claim 12 (original): A method of imaging breast cancer in a patient comprising administering to the patient an antibody of claim 11.

Claim 13 (original): The method of claim 11 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

Attorney Docket No.: **DEX-0471**
Inventors: **Sun et al.**
Serial No.: **Not yet assigned**
Filing Date: **Herewith**
Page 4

Claim 14 (original): A method of treating breast cancer in a patient comprising administering to the patient an antibody of claim 11.

Claim 15 (original): The method of claim 14 wherein the antibody is conjugated to a cytotoxic agent.

Claim 16 (original): A method of treating breast cancer in a patient comprising administering to the patient a molecule which modulates expression or activity of BSG.

Claim 17 (original): The method of claim 16 wherein the molecule downregulates expression or activity of BSG comprising Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4 or SEQ ID NO:10) or Mam005 (SEQ ID NO:3).

Claim 18 (original): The method of claim 16 wherein the molecule upregulates expression or activity of BSG comprising Mam002 (SEQ ID NO:1).

Claim 19 (original): A method of inducing an immune response against a target cell expressing BSG comprising delivering to a human patient an immunogenically stimulatory amount of a BSG protein so that an immune response is mounted against the target cell.